Access to care and financial burden for patients with breast cancer in Ghana, Kenya, and Nigeria.

Authors

null

Majid Twahir

Aga Khan University Hospital, Nairobi, Kenya

Majid Twahir , Rasaaq Adisa Oyesegun , Joel Yarney , Andrew Gachii , Clement Edusa , Chukwumere Nwogu , Gitangu Mangutha , Philip Anderson , Emmanuel Benjamin , Borna Müller , Charles Ngoh

Organizations

Aga Khan University Hospital, Nairobi, Kenya, National Hospital, Maitama, Abuja, Nigeria, Korle Bu Teaching Hospital, Accra, Ghana, Kenyatta National Hospital, Nairobi, Kenya, Sweden Ghana Medical Centre, Accra, Ghana, Lakeshore Cancer Center, Lagos, Nigeria, F. Hoffmann-La Roche Ltd, Nairobi, Kenya, F. Hoffmann-La Roche Ltd, Accra, Ghana, F. Hoffmann-La Roche Ltd, Kaiseraugst, Switzerland, F. Hoffmann-La Roche Ltd, Basel, Switzerland, F. Hoffmann-La Roche, Nairobi, Kenya

Research Funding

Pharmaceutical/Biotech Company

Background: Breast cancer is the most frequently diagnosed malignancy and the most common cause of cancer-related death in women in Ghana, Kenya, and Nigeria. We evaluated healthcare resource use and financial burden for patients treated at tertiary cancer centers in these countries. Methods: Records of breast cancer patients treated at the following government/private tertiary centers were included – Ghana: Korle-Bu Teaching Hospital and Sweden Ghana Medical Centre; Kenya: Kenyatta National Hospital and Aga Khan University Hospital; Nigeria: National Hospital Abuja and Lakeshore Cancer Center. Patients presenting within a prespecified 2-year period were followed until death or loss to follow-up. Results: The study included 299 patient records from Ghana, 314 from Kenya, and 249 from Nigeria. The use of common screening modalities (eg, mammogram, breast ultrasound) was < 45% in all 3 countries. Use of core needle biopsy was 76% in Kenya and Nigeria, but only 50% in Ghana. Across the 3 countries, 91-98% of patients completed blood count/chemistry, whereas only 78-88% completed tests for hormone receptor and human epidermal growth factor receptor 2 (HER2). Most patients underwent surgery: mastectomy (64-67%) or breast-conserving Most patients in Ghana and Nigeria (87-93%) paid for their diagnostic tests entirely out of pocket (OOP) compared with 30-32% in Kenya. Similar to diagnostic testing, the proportion of patients paying OOP only for treatments was high: 72-89% in Nigeria, 45-79% in Ghana, and 8-20% in Kenya. Among those receiving HER2-targeted therapy, average number of cycles was 5 for patients paying OOP only vs 14 for patients with some level of insurance coverage. Conclusions: Patients treated in tertiary facilities in sub-Saharan African countries lack access to common imaging modalities and systemic therapies. Most patients in Ghana and Nigeria bore the full cost of their breast cancer care, suggestive of privileged financial status. Access to screening/diagnosis and appropriate care is likely to be substantively lower for the general population.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research, Clinical Informatics, and Quality of Care

Track

Quality Care/Health Services Research

Sub Track

Access to Care

Clinical Trial Registration Number

PLACEHOLDER NUMBER

Citation

J Clin Oncol 37, 2019 (suppl; abstr 6562)

DOI

10.1200/JCO.2019.37.15_suppl.6562

Abstract #

6562

Poster Bd #

253

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Quality Care Symposium

Physician knowledge and attitudes toward breast cancer screening strategies in transgender population.

First Author: Regina Barragan-Carrillo

Abstract

2022 ASCO Quality Care Symposium

Physician knowledge and attitudes toward breast cancer screening strategies in transgender population.

First Author: Regina Barragan-Carrillo